Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Harvard Business School
McKesson
McKinsey
Mallinckrodt

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Lakeland Regional Medical Center, Inc. v. Astellas US, LLC (M.D. Fla. 2010)

See Plans and Pricing

« Back to Dashboard

Lakeland Regional Medical Center, Inc. v. Astellas US, LLC (M.D. Fla. 2010)

Docket   Start Trial Date Filed 2010-09-13
Court District Court, M.D. Florida Date Terminated 2013-05-16
Cause 15:0001 Antitrust Litigation Assigned To Virginia Maria Hernandez Covin
Jury Demand Plaintiff Referred To Magistrate Judge Thomas G. Wil
Parties ASTELLAS PHARMA US, INC.; ASTELLAS US, LLC; HERBERT STETTIN; LAKELAND REGIONAL MEDICAL CENTER, INC.
Patents 5,070,877; 5,731,296
Attorneys Amanda Arnold Sansone; Andrew E. Brashier; Archie I. Grubb; Brenda L. Danek; Chris S. Coutroulis; Dale E. Thomas; Daniel Greenfield; David M. Schiffman; David P. Frazier; Herbert Stettin; Jack P. Smith , III; James R. Wexler; Jana D. Wozniak; John Treece; Megan M. Walsh; Ronald David Evans , Jr.; Sanya Sukduang; Stephen R. Senn; Susan Haberman Griffen; Timothy R. Fiedler; William B. Raich; Zachary A. Madonia
Firms Beasley Allen Crow Methvin Portis & Miles Pc; Finnegan Henderson Farabow Garrett and Dunner; Finnegan, Henderson, Farabow, Garett & Dunner, LLP; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; Fish & Richardson PC; Herbert Stettin; Leydig, Voit & Mayer, LTD; Office of the Attorney General; Sidley Austin LLP; Sidley, Austin, Brown & Wood
Link to Docket External link to docket
Small Molecule Drugs cited in Lakeland Regional Medical Center, Inc. v. Astellas US, LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Lakeland Regional Medical Center, Inc. v. Astellas US, LLC (M.D. Fla. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-09-13 1 Page 7 of 29 18. United States Patent No. 5,070,877 (the “877 Patent”) relates solely to the use of their…imaging. That patent expired on May 18, 2009. United States Patent No. 5,731,296 (the “296 Patent”), also held…injection. This patent will expire on March 24, 2015. 19. Defendant Astellas believes the ‘296 Patent grants … administered utilizing the process patented by the ‘296 patent. No other medically recognized process…Lexiscan®, and adenosine, generally, are not patented or patentable. Other companies also sell adenosine commercially External link to document
2012-09-24 150 separate method of use patents: the 5,070,877 patent and the 5,731,296 patent. (Levitt Decl. Doc. …The ‘877 Patent expired on May 18, 2009. (Berneman Rpt. at ¶ 16).1 The ‘296 Patent will not… and the ‘296 patents and thus could be liable for patent infringement . . . . [E]…there is no patent that covers the composition, adenosine, this method of use patent …exclusive licensee of two relevant patents involving Case 8:10-cv-02008-VMC-TGW Document External link to document
2011-07-25 66 such patents: the 5,070,877 patent and the 5,731,296 patent. Id. at ¶¶ 17…. Id. Two patents are implicated here. The patents are owned by King … The ‘877 Patent expired on May 18, 2009. Id. The ‘296 Patent covers a method…Both patents encompass the process of using adenosine during myocardial imaging. The patents do not…are administered using the process patented by the ‘296 Patent. Id. No other medically External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
McKesson
Dow
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.